62-9185-41

antibody from Invitrogen Antibodies

Targeting: CXCR5 BLR1, CD185, MDR15

Provider product page for 62-9185-41

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [7]
Comments [0]
Validations
Flow cytometry [1]
Other assay [9]

Submit

Product number: 62-9185-41 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD185 (CXCR5) Monoclonal Antibody (MU5UBEE), Super Bright™ 436, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The MU5UBEE monoclonal antibody reacts with human and non-human primate CD185. CD185, which is also known as C-X-C chemokine receptor 5 (CXCR5) and Burkitt lymphoma receptor 1 (BLR1), is a seven transmembrane G protein-coupled receptor originally identified in Burkitt's lymphoma. In peripheral blood, CD185 is expressed on B cells, CD4+ T cells (but not Th1 or Th2 cells), as well as on a subpopulation of memory (CD45RO+) T cells. Circulating CD185+ T cells are in a resting state and migrate to the lymph nodes due to expression of CCR7 and CD62L. In tonsil, CD185 is expressed on nearly all CD4+ cells together with CD45RO and activation markers such as CD69 and ICOS. Tonsillar CD185+ cells have been shown to induce antibody production when co-cultured with B cells, thus supporting their role in providing help to B cells. Furthermore, this chemokine receptor plays a critical role in lymphocyte trafficking, in particular T cell migration into the B cell follicles of germinal centers in response to CXCL13, making CD185 an established marker of follicular helper T cells. Applications Reported: This MU5UBEE antibody has been reported for use in flow cytometric analysis. Applications Tested: This MU5UBEE antibody has been pre-diluted and tested by flow cytometric analysis of normal human peripheral blood cells. This may be used at 5 µL (1.0 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm. We recommend using a 450/50 bandpass filter, or equivalent. Please make sure that your instrument is capable of detecting this fluorochrome. When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information. Excitation: 405 nm; Emission: 436 nm; Laser: Violet Laser Super Bright Polymer Dyes are sold under license from Becton, Dickinson and Company.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: MU5UBEE
Vial size: 25 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

CXCR5 protein structure - 62-9185-41 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Unchanged cTfh cells and altered Ig profile in sporotrichosis patients. (A) Statistical graphs in the upper row were for CD4 + CXCR5 + Tfh while the lower row were for CD4 + CXCR5 + PD1 + Tfh. The comparison of cTfh percentages were between HC (n = 24) and whole patients (n = 50), patients with different duration (< 6 mon, n = 24; > 6 mon, n = 26) and clinical types (FF, n = 33; LF, n = 17). (B) Comparison of serum levels of total IgG, IgM, and IgE between patients (n = 46) and HC (n = 24). (C, D) Distribution of IgG subtypes (IgG1, IgG2, and IgG3 and IgG4) in patients (in whole: n = 20; SD: n = 7; LD: n = 13) and HC (n = 19). Error bars represent mean+-SD. * P < 0.05, ** P < 0.01, and NS P >= 0.05.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Temporal and spatial dynamics of CXCR5+ NK cells in peripheral lymph nodes during primary SIVagm infection (A) Gating strategy of CXCR5+ NK cells in pLN. NK cells were gated as CD45 + CD3 - CD20 - NKG2A/C + CXCR5 + cells as previously reported (; , p. 80). A representative image is shown. The example corresponds to pLN cells from an African Green Monkey infected by SIVagm at day 9 post-infection. (B) Kinetic of CXCR5 + NK cell percentages in pLN during SIVagm infection, dpi = days post-infection. Each green circle indicates an individual animal (depending on the time point, n = 3 or 6 AGM); p value = *

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 CXCR5+ NK cell induction and gene expression profile (A) Staining of NK cells co-cultured with autologous B cells separated by a transwell membrane illustrating CXCR5 expression on NK cells. The CD3 labeling is used here as a negative control. (B) Dot plot representative of CXCR5+ NK cells from uninfected AGM after 6 days of culture: NK cells cultured alone and NK cells co-cultured with autologous B cells separated by a transwell membrane. (C) The fold change of CXCR5+ NK cell frequencies among total NK cells compared with the frequency of CXCR5+ NK cells in NK cells cultured alone is shown after 6 days of co-culture. B and NK cells were isolated from PBMC of 6 non-infected AGMs (p value = *

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Treatment of Macaques with Antiretroviral Drugs Prior to Collection of PBMCs Leads to a Reduction of Transduction Efficiency with Gammaretroviral Vectors PBMCs from six animals using cells collected prior to treatment with anti-retroviral drugs (Pre-ART) or during antiretroviral treatment (ART) were used in the 9-day transduction and expansion protocol. On day 9, cells were evaluated for expression of MBL, representing the CAR, and CXCR5 by flow cytometry. A Wilcoxon matched pairs signed rank test was used to determine significance. Colors denote cells from six individual animals. The bar represents the median value.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. Longitudinal Sampling of GCs by LN FNA after eOD-GT8 60-mer Immunization (A) Schematic of LN FNA and blood sampling after IM (left) or s.c. (right) immunization. (B) Flow cytometry identification of B GC cell frequencies in the ipsilateral (draining) and contralateral (non-draining) LNs after s.c. and IM immunization. B GC cells are KI67 + BCL6 + . Full gating is Figure S2 . (C) Weekly sampling of B GC cell frequency after one immunization. *p < 0.05, **p < 0.01 (paired t test, one tailed). (D) Flow cytometry identification of GC-T FH cell frequencies in the ipsilateral (draining) and contralateral (non-draining) LNs after s.c. and IM immunization. GC-T FH cells are CXCR5 + PD1 + . (E) Weekly sampling of GC-T FH cell frequency after one immunization. Gated on CD4 + T cells. Each point represents an individual LN FNA sample. n = 8, four LN FNAs per immunization condition at each time point. See also Figures S2 and S3 .